Last updated on November 2019

Multiple Doses of DM199 in Patients With Chronic Kidney Disease

---

Brief description of study

An open-label, Phase II, multi-center study evaluating multiple doses of DM199 in participants with chronic kidney disease.

Detailed Study Description

This is an open-label, Phase II, multi-center study evaluating DM199 in approximately 60 (sixty) Participants in two cohorts.

Cohort I: African Americans with CKD (Stage II or III), hypertension and non-diabetic Cohort II: Participants with IgA nephropathy diagnosis and CKD (Stage II or III)

Participants in each cohort will be enrolled in a parallel assignment to one of two doses:

Dose 1: DM199 2.0 g/kg SC 2x week for 95 days Dose 2: DM199 5.0 g/kg SC 2x week for 95 days